ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Sierra Oncology licenses myelofibrosis candidate from AstraZeneca
August 09, 2021Under a new agreement, AstraZeneca will licence AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode, to Sierra Oncology. -
Sierra’s Momelotinib Granted FDA Fast Track Designation
June 20, 2019Underscores potential for momelotinib to address unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK inhibitor. -
Gilead pays $50M to team up with synthetic lethality startup Tango
November 02, 2018Gilead is paying $50 million upfront to enter into an immuno-oncology collaboration with Tango Therapeutics. The agreement gives Gilead the option to pick up the worldwide rights to five targets...
Pharma Sources Insight January 2025
